Director, Publications
Regeneron Pharmaceuticals
Summary
Director, Publications brings leadership to cross-functional and alliance-wide Publications teams via oversight of publication plan development and implementation (communication objectives, tactical planning) supporting medical strategies for assigned asset(s). This position is accountable for the strategic direction, operational performance, and overall outcomes of assigned publications plans, working in close collaboration with authors, Medical Affairs TA franchise partners, cross-functional stakeholders, and external agency partners. The ideal candidate brings a transparent, team-oriented, and agile mindset, adapting readily to evolving business needs, and consistently prioritizing what is best for the team and the broader organization over individual preferences.
Job description
Essential functions:
- Lead and remain accountable for cross-functional and alliance-wide publications team(s)
- Lead publications review of annual plans and projects with senior management as needed
- Lead in defining and building consensus on terms for literature and gap analyses to support scientific communication platform development and publication strategy
- Pub plan and medical communication strategy development and evolution
- Partner with procurement for agency selection and agency performance management
- Budget accountability for agency/ external resource scope of work (SOW) development, budget tracking, and invoicing according to approved SOW/PO
- Manage writers/agencies for individual pubs projects to effectively complete execution within specified timelines
- Lead the development, management, and execution of Medical Publication Plans, including clinical manuscripts, abstracts, and scientific meeting presentations, ensuring scientific rigor and regulatory compliance at every stage.
- Responsibility for alignment on scientific content/communication objectives, author invitations, collection of author agreements, securing medical/clinical lead materials for kick-off meeting discussions, author kick-off calls
- Review all assigned publications to ensure quality, alignment with scientific communication platform, and compliance with standards for ethical reporting of study data
- Oversee efficient and compliant financial management
- Ensure full adherence to established compliance, regulatory, and ethical standards across all publication activities, including disclosure requirements, TOV guidelines, billing practices, and review documentation
- Proactively identify and communicate operational risks, delays, or issues affecting the team, bringing forward proposed solutions and ensuring timely escalation with recommended paths forward.
- Working with Executive Director, Publications identify and lead meaningful process improvements and innovations initiatives, as appropriate based on business needs
Requirements
- Leadership in cross-functional and alliance-wide publications teams
- Experience in medical communications and publication planning
- Budget management and agency oversight
- Regulatory compliance and ethical reporting standards
- Strategic and tactical planning skills
- Project management and cross-functional collaboration
- Scientific writing and data reporting
- Process improvement and risk management
Benefits
- Annual bonuses
- Incentive plans
- Equity awards
- Pension or retirement benefits
- 401(k) company match
- Health and wellness programs
- Fitness centers
- Insurance benefits
- Paid time off
- Family support benefits
Company overview
Regeneron Pharmaceuticals is a leading American biotechnology company founded in 1988 and headquartered in Tarrytown, New York. The company specializes in inventing, developing, and commercializing life-transforming medicines for people with serious diseases. Regeneron is renowned for its innovative antibody technologies and has developed several groundbreaking therapies, including EYLEA® for retinal diseases, DUPIXENT® for inflammatory conditions, and the COVID-19 antibody cocktail REGEN-COV®. The company operates with a strong focus on research and development across multiple therapeutic areas including ophthalmology, oncology, cardiovascular diseases, and rare genetic disorders. Regeneron's proprietary VelocImmune® technology platform enables the rapid generation of fully human monoclonal antibodies. With over 15,000 employees globally and annual revenues exceeding $14 billion, Regeneron has established itself as a major force in the biotechnology industry, consistently ranking among the top-performing pharmaceutical companies and maintaining a robust pipeline of investigational therapies.